Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on August 9, 2022. The filing serves to announce the Company's financial results for the period ended June 30, 2022, and provides an update on recent corporate events. The report includes a press release and a letter to stockholders as Exhibits 99.1 and 99.2, respectively.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) and letter to stockholders (Exhibit 99.2), which are not included in the source text provided for this summary.
Material Changes and Corporate Events
The filing indicates an update on "recent corporate events" alongside the financial results for the period ended June 30, 2022. Specific details regarding material changes versus prior periods are not disclosed in the body of this 8-K form.
Guidance, Outlook, and Risks
The Company furnished a corporate presentation (Exhibit 99.3) intended for use by management at investor conferences. The filing explicitly states that the information furnished under Items 2.02 and 7.01, including the exhibits, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Furthermore, the Company does not assume any obligation to update the information contained in these exhibits in the future.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the period ended June 30, 2022.
- Examine Exhibit 99.2 (Letter to Stockholders) for details on the "recent corporate events" mentioned in the filing.
- Analyze Exhibit 99.3 (Corporate Presentation) for management's outlook and strategic updates.
- Verify the status of the 8.625% Senior Notes due 2026 (Trading Symbol: HROWL) listed as registered securities.